Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)

An Open-Label, Randomized, 2-Period, Single-Dose, Balanced, Crossover Study in Healthy Subjects to Establish the Bioequivalence of the 20% and 30% Etoricoxib (MK0663) Formulations

This study will establish the bioequivalence of the 20%, milled, roller compaction final market image (FMI) etoricoxib tablets and 30% unmilled, roller compaction (UMC) etoricoxib tablets.

Inclusion Criteria:

• Subject is in good health
• Subject agrees to follow the study guidelines

Exclusion Criteria:

• Subject is a smoker
• Subject has a history of adverse reactions caused by NSAIDs or allergies/intolerance to NSAIDs
• Subject is in a situation or has a condition/disease which may interfere with optimal participation in the study